Prothena Corp (PRTA) Stock Price, Quote & News

Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antib...

Industry: Biotechnology

Sector: Healthcare

Phone: 353 1 236 2500

Fax: 353 1 902 3510

Website: www.prothena.com

Address:

77 Sir John Rogerson’s Quay, Block C Grand Canal Docklands, Dublin, Ireland

buyandsold Jul. 16 at 7:08 PM

$PRTA 1/3 of my port in this.

0 · Reply

alromofi777 Jul. 16 at 2:43 PM

$PRTA 🚀

0 · Reply

AIIAAIIA_88 Jul. 15 at 7:39 PM

$PRTA Hello, managers. It is officially 2H 2025. Just saying. Finally, it’s about time that you do something right for the company and the stock price. Just saying.

0 · Reply

Quantum_Capital_LLC Jul. 10 at 8:37 PM

$PRTA Needs to break out of the 6.5/6.75 bind then we can possibly see 9.25 after; going to be tough. Do your DD. Long term

0 · Reply

sepsis74 Jul. 9 at 1:00 AM

$PRTA looks like EcoR1 bailed completely.

2 · Reply

AIIAAIIA_88 Jul. 1 at 4:34 PM

$PRTA Here we go. PRTA has P3 coming up with Roche for early PD. Of course, it has AD vaccine P1 readouts during the rest of the year. The potential is enormous. Now with less potential competitors after the INMB disaster. ANVS and ALEC before that. AD and PD space is still untapped, urgent needs. Even BP’s failed. LFG, PRTA! $300 by the end of this year! HUGE!

0 · Reply

AIIAAIIA_88 Jun. 29 at 7:33 PM

$PRTA This should begin to go up steadily until August readout. JMO

0 · Reply

AIIAAIIA_88 Jun. 27 at 12:06 PM

$PRTA Watching INMB reporting its AD P1 data on Monday. I doubt it will succeed. Bullish for PRTA. JMO

0 · Reply

Quantum_Capital_LLC Jun. 26 at 7:17 PM

$PRTA looks like a similar story from NTLA, been crushed hard in the last 24 months, 70 all the way down to current. Might be ready for a rebound. See chart, do you DD.

0 · Reply

YaBoy720 Jun. 26 at 2:51 AM

$PRTA I'm a Buyer Tomorrow Bullish

0 · Reply

Prothena Announces Corporate Restructuring

Jun 16, 2025, 1:06 AM EDT - 4 weeks ago

Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

May 27, 2025, 7:43 AM EDT - 7 weeks ago

Why Is Prothena Stock Trading Lower On Tuesday?

May 23, 2025, 4:05 PM EDT - 7 weeks ago

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint

May 9, 2025, 7:16 AM EDT - 2 months ago

Top 3 Health Care Stocks That Are Preparing To Pump This Quarter

RXST SRPT

May 8, 2025, 4:05 PM EDT - 2 months ago

Prothena Reports First Quarter 2025 Financial Results and Business Highlights

May 1, 2025, 4:05 PM EDT - 2 months ago

Prothena to Report First Quarter 2025 Financial Results on May 8

Feb 20, 2025, 8:45 PM EST - 5 months ago

Prothena Corporation plc (PRTA) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 4:05 PM EST - 5 months ago

Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights

Feb 17, 2025, 6:10 PM EST - 5 months ago

Kuehn Law Encourages Investors of Prothena Corporation PLC to Contact Law Firm

Feb 13, 2025, 4:05 PM EST - 5 months ago

Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

Dec 30, 2024, 4:05 PM EST - 7 months ago

Prothena Announces Board of Directors Update

Dec 19, 2024, 1:05 AM EST - 7 months ago

Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease

Nov 12, 2024, 4:05 PM EST - 8 months ago

Prothena Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 5, 2024, 4:05 PM EST - 9 months ago

Prothena to Report Third Quarter 2024 Financial Results on November 12

Sep 27, 2024, 4:05 PM EDT - 10 months ago

Prothena Announces Leadership Team Updates

Aug 29, 2024, 4:05 PM EDT - 11 months ago

Prothena to Participate in Upcoming Healthcare Conferences

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Prothena Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 1, 2024, 4:05 PM EDT - 1 year ago

Prothena to Report Second Quarter 2024 Financial Results on August 8

May 28, 2024, 4:05 PM EDT - 1 year ago

Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration

May 8, 2024, 4:05 PM EDT - 1 year ago

Prothena Reports First Quarter 2024 Financial Results and Business Highlights

May 1, 2024, 4:05 PM EDT - 1 year ago

Prothena to Report First Quarter 2024 Financial Results on May 8

Apr 15, 2024, 4:05 PM EDT - 1 year ago

Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma

Mar 4, 2024, 4:05 PM EST - 1 year ago

Prothena Appoints David Ford to Newly Created Chief People Officer Position

Feb 23, 2024, 12:31 PM EST - 1 year ago

Prothena: Alzheimer's Data Update In 2024 Could Move The Needle

Feb 21, 2024, 4:05 PM EST - 1 year ago

Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate

Feb 15, 2024, 11:53 PM EST - 1 year ago

Prothena Corporation plc (PRTA) Q4 2023 Earnings Call Transcript

Feb 15, 2024, 4:05 PM EST - 1 year ago

Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights

Feb 8, 2024, 4:05 PM EST - 1 year ago

Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024

Jan 8, 2024, 8:30 AM EST - 1 year ago

Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

Nov 2, 2023, 4:05 PM EDT - 1 year ago

Prothena Reports Third Quarter 2023 Financial Results and Business Highlights

Oct 26, 2023, 4:05 PM EDT - 1 year ago

Prothena to Report Third Quarter 2023 Financial Results on November 2

Oct 16, 2023, 11:57 AM EDT - 1 year ago

Prothena prepares for potential sale - Bloomberg News

Sep 21, 2023, 1:39 PM EDT - 1 year ago

Prothena: Switching From 'Hold' To 'Buy' On Lead Alzheimer's Drug Promise

Aug 3, 2023, 4:05 PM EDT - 2 years ago

Prothena Reports Second Quarter 2023 Financial Results and Business Highlights

Jul 27, 2023, 4:05 PM EDT - 2 years ago

Prothena to Report Second Quarter 2023 Financial Results on August 3

Jul 27, 2023, 7:23 AM EDT - 2 years ago

Prothena: Dunn Appointment And Bristol Opt-In Boost Validation

Jul 17, 2023, 8:35 AM EDT - 2 years ago

Prothena Presents New Research in the Treatment of Alzheimer's Disease at Alzheimer's Association International Conference® 2023 (AAIC®)

Jul 11, 2023, 4:05 PM EDT - 2 years ago

Prothena to Present New Data from Alzheimer's Disease Programs at Alzheimer's Association International Conference® 2023 (AAIC®)

Jul 10, 2023, 4:10 PM EDT - 2 years ago

Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau Antibody

Jun 27, 2023, 4:05 PM EDT - 2 years ago

Prothena Announces Phase 3 VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV AL Amyloidosis Treated with Birtamimab

Jun 2, 2023, 4:05 PM EDT - 2 years ago

Prothena to Participate in Jefferies 2023 Healthcare Conference

May 16, 2023, 4:05 PM EDT - 2 years ago

Prothena Announces Appointment of Billy Dunn, M.D., to its Board of Directors

May 7, 2023, 2:28 AM EDT - 2 years ago

Prothena Biosciences' Unique Approach To Protein Misfolding Could Be The Future

May 4, 2023, 4:05 PM EDT - 2 years ago

Prothena Reports First Quarter 2023 Financial Results and Business Highlights

Apr 27, 2023, 4:05 PM EDT - 2 years ago

Prothena to Report First Quarter 2023 Financial Results on May 4

Apr 24, 2023, 4:05 PM EDT - 2 years ago

Prothena to Participate in 2023 Bank of America Healthcare Conference

Apr 13, 2023, 8:00 AM EDT - 2 years ago

Walgreens and Prothena Partner to Increase Access and Enrollment in Alzheimer's Disease Clinical Trial

WBA

Mar 31, 2023, 9:20 AM EDT - 2 years ago

Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023

Mar 21, 2023, 4:05 PM EDT - 2 years ago

Prothena to Participate in Stifel 2023 Virtual CNS Days

buyandsold Jul. 16 at 7:08 PM

$PRTA 1/3 of my port in this.

0 · Reply

alromofi777 Jul. 16 at 2:43 PM

$PRTA 🚀

0 · Reply

AIIAAIIA_88 Jul. 15 at 7:39 PM

$PRTA Hello, managers. It is officially 2H 2025. Just saying. Finally, it’s about time that you do something right for the company and the stock price. Just saying.

0 · Reply

Quantum_Capital_LLC Jul. 10 at 8:37 PM

$PRTA Needs to break out of the 6.5/6.75 bind then we can possibly see 9.25 after; going to be tough. Do your DD. Long term

0 · Reply

sepsis74 Jul. 9 at 1:00 AM

$PRTA looks like EcoR1 bailed completely.

2 · Reply

AIIAAIIA_88 Jul. 1 at 4:34 PM

0 · Reply

AIIAAIIA_88 Jun. 29 at 7:33 PM

$PRTA This should begin to go up steadily until August readout. JMO

0 · Reply

AIIAAIIA_88 Jun. 27 at 12:06 PM

$PRTA Watching INMB reporting its AD P1 data on Monday. I doubt it will succeed. Bullish for PRTA. JMO

0 · Reply

Quantum_Capital_LLC Jun. 26 at 7:17 PM

$PRTA looks like a similar story from NTLA, been crushed hard in the last 24 months, 70 all the way down to current. Might be ready for a rebound. See chart, do you DD.

0 · Reply

YaBoy720 Jun. 26 at 2:51 AM

$PRTA I'm a Buyer Tomorrow Bullish

0 · Reply

SQUEAKSBANDIT Jun. 25 at 12:18 AM

$PRTA sold above $6 then took another look cash runway looks to go through mid 2029 not sure that matters as the next piece of good data will likely motivate the partner to make a bid and buy the whole package way undervalued @ $6 bought some back and will will add on weakness I'm not saying we ever see $70 again but $20 sometime next year seems reasonable

0 · Reply

takingstock73 Jun. 23 at 9:22 PM

$PRTA decent volume today

0 · Reply

alromofi777 Jun. 23 at 5:33 PM

$PRTA 🚀 1,000 shares and holding until we get to $80

1 · Reply

Winning_calls Jun. 23 at 1:50 PM

$PRTA keep👊👊👊

0 · Reply

Winning_calls Jun. 23 at 1:44 PM

$PRTA enjoy that members 🤞🤞

0 · Reply

RandomInvestor777 Jun. 23 at 5:30 AM

Why get into this right now when it'll be at $2-3 after august readout disappointment? The next readout in August requires a very high statistical significance which is higher than average FDA requirement. It's very likely to fail that. $PRTA

1 · Reply

Winning_calls Jun. 23 at 4:18 AM

$PRTA pick me up @ $6

0 · Reply

BioRich Jun. 20 at 4:22 PM

$PRTA Happily doubled my position here. Lucky to load up on this gem. Foresee exciting short-term and long-term potential here. Recent pull back allows for tremendous investment here. Lots of shots on goal and appears to be a winner. Follow/Subscribe for more suggestions and perspective. Would love to hear yours, too. That's how we find these gems and learn. Let's make some money. Cheers! $XBI $PFE $GILD $LLY

1 · Reply

JarvisFlow Jun. 20 at 1:15 PM

Cantor Fitzgerald has updated their rating for Prothena Corp ( $PRTA ) to Neutral.

0 · Reply

StocktwitsNews Jun. 20 at 4:26 AM

Prothena Shares Get A Boost After Company Slashes Workforce, Lowers 2025 Cash Burn Forecast $PRTA https://stocktwits.com/news/equity/markets/prothena-shares-get-a-boost-after-company-slashes-workforce-lowers-2025-cash-burn-forecast/chlx3tpRR2y

0 · Reply

topstockalerts Jun. 19 at 4:44 PM

$PRTA following closely🚨🏦🚨

0 · Reply

alromofi777 Jun. 19 at 4:02 PM

$PRTA 🚀 This thing is gonna fly. Zoom out and get a better look of what will happen 🧐

0 · Reply

Market Cap	346.11M
Revenue (ttm)	135.16M
Net Income (ttm)	-122.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-90.49%
Debt to Equity Ratio	0.00

Volume	418,203
Avg Vol	2,026,024
Day's Range	N/A - N/A
Shares Out	53.83M
Stochastic %K	14%
Beta	0.01
Analysts	Sell
Price Target	$24.29